AbbVie (ABBV): Buy, Sell, or Hold Post Q4 Earnings?
Over the past six months, AbbVie has been a great trade, beating the S&P 500 by 5.6%. Its stock price has climbed to $233.25, representing a healthy 1...
Last updated: 2026-03-07 13:59:49 ET
Over the past six months, AbbVie has been a great trade, beating the S&P 500 by 5.6%. Its stock price has climbed to $233.25, representing a healthy 1...
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Eli Lilly and Company, Medline, Johnson & Johnson, AbbVie, UnitedHealth Group, Merck & Co., Inc., and McKesson are the seven Medical stocks to watch t...
ABBV's neuroscience unit delivered $10.8B in 2025 and can hit $12.5B in 2026 as Vyalev gains traction and new Parkinson's drug tavapadon awaits FDA re...
AbbVie (NYSE:ABBV) plans to invest US$380 million in two new US active pharmaceutical ingredient manufacturing facilities that will use artificial int...
In the most recent trading session, AbbVie (ABBV) closed at $232.35, indicating a -1.63% shift from the previous trading day.
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE